Treatment of Barth Syndrome by Cardiolipin Manipulation (CARDIOMAN) With Bezafibrate: Protocol for a Randomized Placebo-Controlled Pilot Trial Conducted in the Nationally Commissioned Barth Syndrome Service

The Effects of PPAR Stimulation on Cardiac Metabolic Pathways in Barth Syndrome Mice

(2018) Caitlin Schafer et al.   Frontiers in Pharmacology

Neutropenia in Barth syndrome

(2018) Colin G. Steward et al.   CURRENT OPINION IN HEMATOLOGY

The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome

(2017) Yan Huang et al.   Orphanet Journal of Rare Diseases

Loss of protein association causes cardiolipin degradation in Barth syndrome

(2016) Yang Xu et al.   Nature Chemical Biology

The relationship between biventricular myocardial performance and metabolic parameters during incremental exercise and recovery in healthy adolescents

(2015) Guido E. Pieles et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Lifespan and healthspan extension by resveratrol

(2015) Khushwant S. Bhullar et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Barth syndrome

(2013) Sarah LN Clarke et al.   Orphanet Journal of Rare Diseases

Recommendations for Quantification Methods During the Performance of a Pediatric Echocardiogram: A Report From the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council

(2010) Leo Lopez et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

Long-term Benefit of High-Density Lipoprotein Cholesterol–Raising Therapy With Bezafibrate

(2009) Ilan Goldenberg et al.   ARCHIVES OF INTERNAL MEDICINE